<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2016-1S-35-37</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-600</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Status epilepticus: Analysis of refractory cases</article-title><trans-title-group xml:lang="ru"><trans-title>Эпилептический статус: анализ рефрактерных случаев</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гладов</surname><given-names>Б. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Gladov</surname><given-names>B. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нервных болезней лечебного факультета</p></bio><bio xml:lang="en"><p>Department of Nervous System Diseases, Faculty of General Medicine</p></bio><email xlink:type="simple">gladovboris@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подгорная</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Podgornaya</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нервных болезней лечебного факультета</p></bio><bio xml:lang="en"><p>Department of Nervous System Diseases, Faculty of General Medicine</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власов</surname><given-names>П. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasov</surname><given-names>P. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нервных болезней лечебного факультета</p></bio><bio xml:lang="en"><p>Department of Nervous System Diseases, Faculty of General Medicine</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Evdokimov Moscow State University of Medicine and Dentistry</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>15</day><month>07</month><year>2016</year></pub-date><volume>0</volume><issue>1S</issue><fpage>35</fpage><lpage>37</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Gladov B.P., Podgornaya O.A., Vlasov P.N., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Гладов Б.П., Подгорная О.А., Власов П.Н.</copyright-holder><copyright-holder xml:lang="en">Gladov B.P., Podgornaya O.A., Vlasov P.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/600">https://nnp.ima-press.net/nnp/article/view/600</self-uri><abstract><p>Objective: to analyze refractory status epilepticus (SE) cases.Patients and methods. Fifteen female patients aged 21 to 62 years with refractory SE were comprehensively examined using long-term electroencephalography monitoring. The investigators evaluated the efficiency of treatment regimens with intravenous antiepileptic drugs (AEDs), such as diazepam (DZP); valproic acid (VPA); levetiracetam; and lacosamide and their combinations, at the prehospital and hospital stages, as well as SE therapy complications noted only in the intravenous administration of narcotics (propofol, sodium thiopental).Results and discussion. A fetal outcome due to multiple organ dysfunction indirectly related to SE was recorded in 2 (13.3%) patients with acute symptomatic status. SE was abolished in the other 13 cases. The preliminary findings may suggest that it is appropriate to prescribe VPA just at the prehospital stage. The co-administration of VPA and DZP substantially enhances the efficiency of SE therapy. The maximum acceptable doses of AEDs using the whole available therapeutic arsenal should be administered within the first hours of acute symptomatic SE.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования – анализ рефрактерных случаев эпилептического статуса (ЭС).Пациенты и методы. Комплексно с использованием длительного электроэнцефалографического мониторинга обследовано 15 пациентов с рефрактерным ЭС (все женщины) в возрасте от 21 года до 62 лет. Оценивалась эффективность схем лечения внутривенными формами противоэпилептических препаратов (ПЭП): диазепама (ДЗП); вальпроевой кислоты (ВК); леветирацетама(ЛЕВ); лакосамида и их комбинаций – на догоспитальном и госпитальном этапе, а также осложнения терапии ЭС, отмеченные только при введении средств для внутривенного наркоза (пропофол, тиопентал натрия).Результаты и обсуждение. У 2 (13,3%) пациенток с острым симптоматическим статусом был зарегистрирован летальный исход вследствие полиорганной недостаточности, не связанной непосредственно с ЭС. В остальных 13 случаях ЭС купирован. Пред-варительные данные позволяют предположить целесообразность назначения ВК уже на догоспитальном этапе. Одновременное применение ВК и ДЗП существенно повышает эффективность терапии ЭС. При остром симптоматическом ЭС следует в первые часы назначать максимально допустимые дозы ПЭП с использованием всего доступного терапевтического арсенала.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эпилептический статус</kwd><kwd>фокальная эпилепсия</kwd><kwd>острый симптоматический статус</kwd><kwd>рефрактерный эпилептиче- ский статус</kwd><kwd>леветирацетам</kwd><kwd>лакосамид</kwd><kwd>вальпроевая кислота</kwd><kwd>диазепам</kwd></kwd-group><kwd-group xml:lang="en"><kwd>status epilepticus</kwd><kwd>partial epilepsy</kwd><kwd>acute symptomatic status</kwd><kwd>refractory status epilepticus</kwd><kwd>levetiracetam</kwd><kwd>lacosamide</kwd><kwd>valproic acid</kwd><kwd>diazepam</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">DeLorenzo RJ, Hauser WA, Towne AR. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. Apr 1996;46(4):1029-35. doi: 10.1212/WNL.46.4.1029</mixed-citation><mixed-citation xml:lang="en">DeLorenzo RJ, Hauser WA, Towne AR. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. Apr 1996;46(4):1029-35. doi: 10.1212/WNL.46.4.1029</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia. 2007;48 Suppl. 8:82-4. doi: 10.1111/j.1528-167.2007.01359.x</mixed-citation><mixed-citation xml:lang="en">Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia. 2007;48 Suppl. 8:82-4. doi: 10.1111/j.1528-167.2007.01359.x</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51:671-5. doi: 10.1111/j.1528-1167.2009.02285.x</mixed-citation><mixed-citation xml:lang="en">Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51:671-5. doi: 10.1111/j.1528-1167.2009.02285.x</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults. Lancet Neurol. 2011;10:922-30. doi: 10.1016/S1474-4422(11)70187-9</mixed-citation><mixed-citation xml:lang="en">Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults. Lancet Neurol. 2011;10:922-30. doi: 10.1016/S1474-4422(11)70187-9</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shorvon S, Ferlisi M. The Treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(10):2802-18.doi: 10.1093/brain/awr215</mixed-citation><mixed-citation xml:lang="en">Shorvon S, Ferlisi M. The Treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(10):2802-18.doi: 10.1093/brain/awr215</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Власов ПН. Внутривенные формы противоэпилептических препаратов в России. Неврология, нейропсихиатрия, психосоматика. 2014;6(1S):48-53 [Vlasov PN. Intravenous Antiepileptic Drugs in Russia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(1S):48-53. (In Russ.)]. doi: 10.14412/2074-2711-2014-1S-48-53</mixed-citation><mixed-citation xml:lang="en">Власов ПН. Внутривенные формы противоэпилептических препаратов в России. Неврология, нейропсихиатрия, психосоматика. 2014;6(1S):48-53 [Vlasov PN. Intravenous Antiepileptic Drugs in Russia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(1S):48-53. (In Russ.)]. doi: 10.14412/2074-2711-2014-1S-48-53</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Karlov VA. Mechanisms of Brain Antiepileptic Defense, (abstr). 20th International Epilepsy Congress, Oslo, Norway. Epilepsia. 1993;34 Suppl 2:47.</mixed-citation><mixed-citation xml:lang="en">Karlov VA. Mechanisms of Brain Antiepileptic Defense, (abstr). 20th International Epilepsy Congress, Oslo, Norway. Epilepsia. 1993;34 Suppl 2:47.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rossetti F, de Araujo Furtado M, Pak T, et al. Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure. Neurotoxicology. 2012 Jun;33(3):500-11. doi: 10.1016/j.neuro.2012.02.010</mixed-citation><mixed-citation xml:lang="en">Rossetti F, de Araujo Furtado M, Pak T, et al. Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure. Neurotoxicology. 2012 Jun;33(3):500-11. doi: 10.1016/j.neuro.2012.02.010</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Карлов ВА. Эпилепсия у детей и взрослых, женщин и мужчин. Москва: Медицина; 2010. 720 с. [Karlov VA. Epilepsiya u detei i vzroslykh, zhenshchin i muzhchin [Epilepsy in children and adults, women and men]. Moscow: Medicina; 2010. 720 p.].</mixed-citation><mixed-citation xml:lang="en">Карлов ВА. Эпилепсия у детей и взрослых, женщин и мужчин. Москва: Медицина; 2010. 720 с. [Karlov VA. Epilepsiya u detei i vzroslykh, zhenshchin i muzhchin [Epilepsy in children and adults, women and men]. Moscow: Medicina; 2010. 720 p.].</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014 Feb 25;82(8):656-64. doi:10.1212/WNL.0000000000000009</mixed-citation><mixed-citation xml:lang="en">Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014 Feb 25;82(8):656-64. doi:10.1212/WNL.0000000000000009</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
